Copy Link Print Information

Sutacimig

(Synonyms: HMB-001)
Revisión del cliente

Based on 1 Customer Validation

Sutacimig (HMB-001) is a humanized antibody of the (H-γ4_L-κ)_(H-γ4_L-κ) format that targets FⅦa/TREML1. One arm of Sutacimig binds to endogenous FVIIa, thereby prolonging the half-life of FVIIa and increasing its accumulation in the bloodstream, while the other arm binds to TLT-1, which is exclusively expressed on the surface of activated platelets. This localizes endogenous FVIIa to activated platelets, further enhancing the activity of FVIIa. Sutacimig enhances Thrombin generation, fibrin formation, and the formation of stable fibrin-platelet networks at sites of vascular injury. Sutacimig can be used in studies related to Glanzmann thrombasthenia.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza: 99.08%
  • No. CAS: 2933972-64-4
  • Peso molecular:144.54 kDa
  • Almacenamiento:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Sutacimig
  • Experimental Validation Results for Sutacimig
  • Experimental Validation Results for Sutacimig
  • Sutacimig Chemical Structure
    Sutacimig Chemical Structure
No. CAS: 2933972-64-4
Tamaño
Precio
Stock
Cantidad
Amount: USD 0.00
Please select quantity
or
or

* Seleccione Cantidad antes de agregar artículos.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Sutacimig Product Recommendations:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Encuentre su distribuidor local Your local distributor: Hycultec GmbHHycultec
  • Actividad biológica
  • Chemical Information
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Ver todos los productos específicos de isoformas TREM receptor

More

Keywords

MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Inicie sesiòn
Registrar
Sign in to MedChemExpress
Registrar una cuenta nueva

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    IgG4-kappa

  • 1/16

    Immobilized Coagulation factor VII/F7 Protein, Human (HEK293, His, HY-P78763) can bind Sutacimig. The EC50 for this effect is 10.01 ng/mL.

  • 1/16

    Flow cytometric analysis of 1.5×106 Jurkat cells with Sutacimig (HY-P991029, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • Sutacimig Chemical Structure
    1/16
  • Sutacimig
  • Immobilized Coagulation factor VII/F7 Protein, Human (HEK293, His, HY-P78763) can bind Sutacimig. The EC50 for this effect is 10.01 ng/mL.
  • Flow cytometric analysis of 1.5×106 Jurkat cells with Sutacimig (HY-P991029, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
  • IgG4-kappa